Cancer‑testis antigens are predominantly expressed in uterine leiomyosarcoma compared with non‑uterine leiomyosarcoma

Iura, Kunio; Kohashi, Kenichi; Yasutake, Nobuko; Ishii, Takeaki; Maekawa, Akira; Bekki, Hirofumi; Otsuka, Hiroshi; Yamada, Yuichi; Yamamoto, Hidetaka; Ohishi, Yoshihiro; Matsumoto, Yoshihiro; Iwamoto, Yukihide; Oda, Yoshinao

doi:10.3892/ol.2017.7274

Cited by 3 publications

(4 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NY-ESO-1 has been shown to be at least focally expressed in malignant peripheral nerve sheath tumors, uterine (40,41). Expression has not been seen in non-uterine leiomyosarcomas (41).…”

Section: Ny-eso-1 and Other Sarcomasmentioning

confidence: 99%

“…NY-ESO-1 has been shown to be at least focally expressed in malignant peripheral nerve sheath tumors, uterine (40,41). Expression has not been seen in non-uterine leiomyosarcomas (41). Intriguingly, though the molecular underpinnings of GISTs have recently expanded to include novel subgrouping based on cKIT, SDH and PDGFRA/ B mutations ( 42), it appears that there is some involvement with CTA expression as well.…”

Section: Ny-eso-1 and Other Sarcomasmentioning

confidence: 99%

See 1 more Smart Citation

NY-ESO-1: a promising cancer testis antigen for sarcoma immunotherapy and diagnosis

Smith

Iwenofu

2018

Chin. Clin. Oncol.

View full text Add to dashboard Cite

Sarcomas are heterogenous malignant mesenchymal neoplasms. These are often notoriously difficult to treat particularly in the metastatic setting. There is therefore an urgent need for development of better and more efficacious targeted therapies. Cancer testis antigens (CTAs) are a family of proteins in which aberrant gene-activation and subsequent high level mRNA expression, are restricted to testicular germ cells and are seen in certain malignancies. Importantly, the restriction of this class of antigens to testicular germ cells and malignancies and not somatic tissue, makes them an excellent choice for targeted immunotherapy. The NY-ESO-1is the most immunogenic of CTA and has, of late, become well-studied for its diagnosis and potential treatment implications in sarcomas. This paper reviews both the role of NY-ESO-1 in the diagnosis of sarcomas, as well as the implications of this CTA in vaccine development and treatment of sarcomas.

show abstract

“…NY-ESO-1 has been shown to be at least focally expressed in malignant peripheral nerve sheath tumors, uterine (40,41). Expression has not been seen in non-uterine leiomyosarcomas (41).…”

Section: Ny-eso-1 and Other Sarcomasmentioning

confidence: 99%

Section: Ny-eso-1 and Other Sarcomasmentioning

confidence: 99%

NY-ESO-1: a promising cancer testis antigen for sarcoma immunotherapy and diagnosis

Smith

Iwenofu

2018

Chin. Clin. Oncol.

View full text Add to dashboard Cite

show abstract

“…We also compared the expression profiles of CTAs between uterine leiomyosarcoma (ULMS) and non‐uterine soft tissue leiomyosarcoma (NULMS) . ULMS showed significant frequent expression of MAGEA1, MAGEA3, MAGEA4 and GAGE7, compared with NULMS, suggesting possible utility of these CTAs in ULMS as an immunotherapy target …”

Section: A Molecular‐biologic Approach To Identifying Therapeutic Molmentioning

confidence: 99%

Soft tissue sarcomas: From a morphological to a molecular biological approach

Oda

Kohashi

Yamada

et al. 2017

Pathology International

Self Cite

View full text Add to dashboard Cite

Recently developed molecular genetic techniques have led to the elucidation of tumor-specific genomic alterations and thereby the reclassification of tumor entities of soft tissue sarcoma. A solitary fibrous tumor-mimicking tumor with the AHRR-NCOA2 gene has been isolated as angiofibroma of soft tissue. As for small round cell sarcomas, novel fusion genes such as CIC-DUX4 and BCOR-CCNB3 have been identified in these tumor groups. SMARCB1/INI1 deficient tumors with round cell morphology are also expected to be reclassified in three types, based on the combination of their morphology and genotype. The identification of the MDM2 gene amplification in pleomorphic sarcomas has extended the entity of dedifferentiated liposarcoma (DDLS). Our recent molecular investigations elucidated candidates for novel therapeutic strategies. Activation of the Akt-mTOR pathway was correlated with poor prognosis or tumor grade in spindle cell sarcomas including malignant peripheral nerve sheath tumor. In vitro and in vivo studies of transcription factor Forkhead Box M1 (FOXM1) demonstrated the close correlation between aggressive biological behavior or chemosensitivity and FOXM1 expression in synovial sarcoma, so far. Finally, in regard to the investigation of cancer-testis antigens, myxoid/round cell liposarcoma and synovial sarcoma showed frequent and high expression of PRAME and NY-ESO-1.

show abstract

“…Substantial genetic and histologic heterogeneity of this group makes treatment development very complicated. Nevertheless, STBS are immunogenic because their cells express the broad spectrum of CTA [22][23][24]. The universality of immunologic approaches and possible immunogenic targets in STBS promotes the development of immunotherapeutic methods for their therapy.…”

mentioning

confidence: 99%

Cancer/testis antigens expression during cultivation of melanoma and soft tissue sarcoma cells

Данилова¹,

Misyurin

Novik³

et al. 2020

Clin Sarcoma Res

View full text Add to dashboard Cite

Background: Autologous dendritic cells (DC) loaded with tumor-associated antigens (TAAs) are a promising approach for anticancer immunotherapy. Polyantigen lysates appear to be an excellent source of TAAs for loading onto the patient's dendritic cells. Cancer/testis antigens (CTA) are expressed by a wide range of tumors, but are minimally expressed on normal tissues, and could serve as a universal target for immunotherapy. However, CTA expression levels can vary significantly in patients with the same tumor type. We proposed that patients who do not respond to DC-based therapy may have distinct features of the CTA expression profile on tumor cells. Patients and methods: We compared the gene expression of the principal families CTA in 22 melanoma and 27 soft tissue and bone sarcomas cell lines (STBS), received from patients and used for DC vaccine preparation. Results: The majority (47 of 49, 95.9%) cell lines showed CTA gene activity. The incidence of gene expression of GAGE, NYESO1, MAGEA1, PRAME's was significantly different (adj. p < 0.05) between melanoma and sarcoma cell lines. The expression of the SCP1 gene was detected neither in melanoma cells nor in the STBS cells. Clustering by the gene expression profile revealed four different expression patterns. We found three main patterns types: hyperexpression of multiple CTA, hyperexpression of one CTA with almost no expression of others, and no expression of CTA. All clusters types exist in melanoma and sarcoma cell lines. We observed dependence of killing efficacy from the PRAME (rho = 0.940, adj. p < 0.01) expression during real-time monitoring with the xCELLigence system of the interaction between melanoma or sarcoma cells with the T-lymphocytes activated by the lysate of selected allogenous melanoma cell lines with high expression of CTA. Conclusion: Our results demonstrate that one can use lysates from allogeneic melanoma cell lines as a source of CTA for DC load during the production of anticancer vaccines for the STBS treatment. Patterns of CTA expression should be evaluated as biomarkers of response in prospective clinical trials.

show abstract

Cancer‑testis antigens are predominantly expressed in uterine leiomyosarcoma compared with non‑uterine leiomyosarcoma

Cited by 3 publications

References 35 publications

NY-ESO-1: a promising cancer testis antigen for sarcoma immunotherapy and diagnosis

NY-ESO-1: a promising cancer testis antigen for sarcoma immunotherapy and diagnosis

Soft tissue sarcomas: From a morphological to a molecular biological approach

Cancer/testis antigens expression during cultivation of melanoma and soft tissue sarcoma cells

Contact Info

Product

Resources

About